{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:47:56Z","timestamp":1787741276734,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002661","name":"FNRS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100015400","name":"Fonds Erasme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015400","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European regional 456 Development Fund"},{"DOI":"10.13039\/100016132","name":"Gouvernement Wallon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016132","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fonds Yvonne Bo\u00ebl"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fibroblast activation protein-\u03b1 (FAP\u03b1) is a marker of activated fibroblasts that can be selectively targeted by an inhibitor (FAPI) and visualised by PET\/CT imaging. We evaluated whether the measurement of FAP\u03b1 in bronchoalveolar lavage fluids (BALF) and the uptake of FAPI by PET\/CT could be used as biomarkers of fibrogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The dynamics of lung uptake of\n                      <jats:sup>18<\/jats:sup>\n                      F-labeled FAPI ([\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74) was assessed in the bleomycin mouse model at various time points and using different concentrations of bleomycin by PET\/CT. FAP\u03b1 was measured in BALFs from these bleomycin-treated and control mice. FAP\u03b1 levels were also assessed in BALFs from controls and patients with idiopathic pulmonary fibrosis (IPF).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Bleomycin-treated mice presented a significantly higher uptake of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 during lung fibrinogenesis (days 10 and 16 after instillation) compared to control mice. No significant difference was observed at initial inflammatory phase (3 days) and when fibrosis was already established (28 days). [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 tracer was unable to show a dose-response to bleomycin treatment. On the other hand, BALF FAP\u03b1 levels were steeply higher in bleomycin-treated mice at day 10 and a significant dose-response effect was observed. Moreover, FAP\u03b1 levels were strongly correlated with lung fibrosis as measured by the modified Aschroft histological analysis, hydroxyproline and the percentage of weight loss. Importantly, higher levels of FAP\u03b1 were observed in IPF patients where the disease was progressing as compared to stable patients and controls. Moreover, patients with FAP\u03b1 BALF levels higher than 192.5 pg\/mL presented a higher risk of progression, transplantation or death compared to patients with lower levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our preclinical data highlight a specific increase of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 lung uptake during the fibrotic phase of the bleomycin murine model. The measurement of FAP\u03b1 in BALF appears to be a promising marker of the fibrotic activity in preclinical models of lung fibrosis and in IPF patients. Further studies are required to confirm the role of FAP\u03b1 in BALF as biomarker of IPF activity and assess the relationship between FAP\u03b1 levels in BALF and [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 uptake on PET\/CT in patients with fibrotic lung disease.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-023-02556-6","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T15:01:47Z","timestamp":1698246107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Usefulness of FAP\u03b1 assessment in bronchoalveolar lavage as a marker of fibrogenesis: results of a preclinical study and first report in patients with idiopathic pulmonary fibrosis"],"prefix":"10.1186","volume":"24","author":[{"given":"Philom\u00e8ne","family":"Lavis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Pingitore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Doumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ani","family":"Garabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetan","family":"Van Simaeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Passon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Van Heymbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coraline","family":"De Maeseneire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Allard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Collin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Huaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Decaestecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra Kupper","family":"Cardozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bondue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"2556_CR1","doi-asserted-by":"publisher","first-page":"00597","DOI":"10.1183\/23120541.00597-2021","volume":"8","author":"O Hilberg","year":"2022","unstructured":"Hilberg O, Hoffmann-Vold A-M, Smith V, Bouros D, Kilpel\u00e4inen M, Guiot J, et al. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six european countries. ERJ Open Res. 2022;8:00597\u20132021. https:\/\/doi.org\/10.1183\/23120541.00597-2021","journal-title":"ERJ Open Res"},{"key":"2556_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","volume":"400","author":"M Wijsenbeek","year":"2022","unstructured":"Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet. 2022;400:769\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(22)01052-2","journal-title":"Lancet"},{"key":"2556_CR3","doi-asserted-by":"crossref","first-page":"2s","DOI":"10.1183\/09031936.01.18s320002","volume":"32","author":"M Demedts","year":"2001","unstructured":"Demedts M, Wells AU, Ant\u00f3 JM, Costabel U, Hubbard R, Cullinan P, et al. Interstitial lung diseases: an epidemiological overview. Eur Respir J Suppl. 2001;32:2s\u201316s.","journal-title":"Eur Respir J Suppl"},{"key":"2556_CR4","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. An official American thoracic Society\/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733\u201348. https:\/\/doi.org\/10.1164\/rccm.201308-1483ST","journal-title":"Am J Respir Crit Care Med"},{"key":"2556_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431\u201340. https:\/\/doi.org\/10.1164\/rccm.201006-0894CI","journal-title":"Am J Respir Crit Care Med"},{"key":"2556_CR6","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:e44\u201368. https:\/\/doi.org\/10.1164\/rccm.201807-1255ST","journal-title":"Am J Respir Crit Care Med"},{"key":"2556_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/medsci6020051","volume":"6","author":"E Fern\u00e1ndez Fabrellas","year":"2018","unstructured":"Fern\u00e1ndez Fabrellas E, Peris S\u00e1nchez R, Sabater Abad C, Juan Samper G. Prognosis and Follow-Up of idiopathic pulmonary fibrosis. Med Sci (Basel). 2018;6:51. https:\/\/doi.org\/10.3390\/medsci6020051","journal-title":"Med Sci (Basel)"},{"key":"2556_CR8","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","volume":"156","author":"B Ley","year":"2012","unstructured":"Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156:684\u201391. https:\/\/doi.org\/10.7326\/0003-4819-156-10-201205150-00004","journal-title":"Ann Intern Med"},{"key":"2556_CR9","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1183\/09031936.00146314","volume":"45","author":"B Ley","year":"2015","unstructured":"Ley B, Bradford WZ, Weycker D, Vittinghoff E, du Bois RM, Collard HR. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1374\u201381. https:\/\/doi.org\/10.1183\/09031936.00146314","journal-title":"Eur Respir J"},{"key":"2556_CR10","doi-asserted-by":"publisher","first-page":"00074","DOI":"10.1183\/23120541.00074-2016","volume":"3","author":"Y Bauer","year":"2017","unstructured":"Bauer Y, White ES, de Bernard S, Cornelisse P, Leconte I, Morganti A, et al. MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2017;3:00074\u20132016. https:\/\/doi.org\/10.1183\/23120541.00074-2016","journal-title":"ERJ Open Res"},{"key":"2556_CR11","first-page":"155","volume":"26","author":"NP Barlo","year":"2009","unstructured":"Barlo NP, van Moorsel CHM, Ruven HJT, Zanen P, van den Bosch JMM, Grutters JC. Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26:155\u201361.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2556_CR12","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1378\/chest.08-2209","volume":"135","author":"BW Kinder","year":"2009","unstructured":"Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest. 2009;135:1557\u201363. https:\/\/doi.org\/10.1378\/chest.08-2209","journal-title":"Chest"},{"key":"2556_CR13","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","volume":"5","author":"TM Maher","year":"2017","unstructured":"Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med. 2017;5:946\u201355. https:\/\/doi.org\/10.1016\/S2213-2600(17)30430-7","journal-title":"Lancet Respir Med"},{"key":"2556_CR14","doi-asserted-by":"publisher","first-page":"104766","DOI":"10.1016\/j.ebiom.2023.104766","volume":"95","author":"T Karampitsakos","year":"2023","unstructured":"Karampitsakos T, Juan-Guardela BM, Tzouvelekis A, Herazo-Maya JD. Precision medicine advances in idiopathic pulmonary fibrosis. EBioMedicine. 2023;95:104766. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104766","journal-title":"EBioMedicine"},{"key":"2556_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","volume":"39","author":"AA Fitzgerald","year":"2020","unstructured":"Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39:783\u2013803. https:\/\/doi.org\/10.1007\/s10555-020-09909-3","journal-title":"Cancer Metastasis Rev"},{"key":"2556_CR16","doi-asserted-by":"publisher","first-page":"14028","DOI":"10.1021\/acs.jmedchem.1c01010","volume":"64","author":"L Juillerat-Jeanneret","year":"2021","unstructured":"Juillerat-Jeanneret L, Tafelmeyer P, Golshayan D. Regulation of fibroblast activation Protein-\u03b1 expression: focus on intracellular protein interactions. J Med Chem. 2021;64:14028\u201345. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01010","journal-title":"J Med Chem"},{"key":"2556_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.humpath.2005.11.020","volume":"37","author":"PS Acharya","year":"2006","unstructured":"Acharya PS, Zukas A, Chandan V, Katzenstein A-LA, Pur\u00e9 E. Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Hum Pathol. 2006;37:352\u201360. https:\/\/doi.org\/10.1016\/j.humpath.2005.11.020","journal-title":"Hum Pathol"},{"key":"2556_CR18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","volume":"59","author":"A Loktev","year":"2018","unstructured":"Loktev A, Lindner T, Mier W, Debus J, Altmann A, J\u00e4ger D, et al. A tumor-imaging Method Targeting Cancer-Associated fibroblasts. J Nucl Med. 2018;59:1423\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.210435","journal-title":"J Nucl Med"},{"key":"2556_CR19","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","volume":"60","author":"A Loktev","year":"2019","unstructured":"Loktev A, Lindner T, Burger E-M, Altmann A, Giesel F, Kratochwil C, et al. Development of fibroblast activation protein-targeted Radiotracers with Improved Tumor Retention. J Nucl Med. 2019;60:1421\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.224469","journal-title":"J Nucl Med"},{"key":"2556_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2967\/jnumed.121.261925","volume":"63","author":"M R\u00f6hrich","year":"2022","unstructured":"R\u00f6hrich M, Leitz D, Glatting FM, Wefers AK, Weinheimer O, Flechsig P, et al. Fibroblast activation protein-specific PET\/CT imaging in Fibrotic interstitial lung Diseases and Lung Cancer: a translational exploratory study. J Nucl Med. 2022;63:127\u201333. https:\/\/doi.org\/10.2967\/jnumed.121.261925","journal-title":"J Nucl Med"},{"key":"2556_CR21","doi-asserted-by":"publisher","first-page":"L152","DOI":"10.1152\/ajplung.00313.2007","volume":"294","author":"BB Moore","year":"2008","unstructured":"Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2008;294:L152\u2013160. https:\/\/doi.org\/10.1152\/ajplung.00313.2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2556_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2144\/000112729","volume":"44","author":"R-H H\u00fcbner","year":"2008","unstructured":"H\u00fcbner R-H, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques. 2008;44:507\u201311. https:\/\/doi.org\/10.2144\/000112729","journal-title":"Biotechniques"},{"key":"2556_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2967\/jnumed.114.147421","volume":"56","author":"B Bondue","year":"2015","unstructured":"Bondue B, Sherer F, Van Simaeys G, Doumont G, Egrise D, Yakoub Y, et al. PET\/CT with 18F-FDG- and 18F-FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis. J Nucl Med. 2015;56:127\u201332. https:\/\/doi.org\/10.2967\/jnumed.114.147421","journal-title":"J Nucl Med"},{"key":"2556_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194:265\u201375. https:\/\/doi.org\/10.1164\/rccm.201604-0801CI","journal-title":"Am J Respir Crit Care Med"},{"key":"2556_CR25","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205:e18\u201347. https:\/\/doi.org\/10.1164\/rccm.202202-0399ST","journal-title":"Am J Respir Crit Care Med"},{"key":"2556_CR26","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1007\/s00259-022-05814-9","volume":"49","author":"ZT Rosenkrans","year":"2022","unstructured":"Rosenkrans ZT, Massey CF, Bernau K, Ferreira CA, Jeffery JJ, Schulte JJ, et al. [68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity. Eur J Nucl Med Mol Imaging. 2022;49:3705\u201316. https:\/\/doi.org\/10.1007\/s00259-022-05814-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2556_CR27","doi-asserted-by":"publisher","unstructured":"Yang P, Luo Q, Wang X, Fang Q, Fu Z, Li J et al. Comprehensive Analysis of Fibroblast activation protein expression in interstitial Lung Diseases. Am J Respir Crit Care Med n d;207:160\u201372. https:\/\/doi.org\/10.1164\/rccm.202110-2414OC","DOI":"10.1164\/rccm.202110-2414OC"},{"key":"2556_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12931-017-0556-3","volume":"18","author":"A Justet","year":"2017","unstructured":"Justet A, Laurent-Bellue A, Thabut G, Dieudonn\u00e9 A, Debray M-P, Borie R, et al. [18F]FDG PET\/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis. Respir Res. 2017;18:74. https:\/\/doi.org\/10.1186\/s12931-017-0556-3","journal-title":"Respir Res"},{"key":"2556_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/MNM.0000000000000083","volume":"35","author":"EYP Lee","year":"2014","unstructured":"Lee EYP, Wong CS, Fung SL, Yan PK, Ho JCM. SUV as an adjunct in evaluating disease activity in idiopathic pulmonary fibrosis - a pilot study. Nucl Med Commun. 2014;35:631\u20137. https:\/\/doi.org\/10.1097\/MNM.0000000000000083","journal-title":"Nucl Med Commun"},{"key":"2556_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41824-018-0045-z","volume":"2","author":"A Castiaux","year":"2018","unstructured":"Castiaux A, Van Simaeys G, Goldman S, Bondue B. Assessment of 18F-FDG uptake in idiopathic pulmonary fibrosis: influence of lung density changes. Eur J Hybrid Imaging. 2018;2:27. https:\/\/doi.org\/10.1186\/s41824-018-0045-z","journal-title":"Eur J Hybrid Imaging"},{"key":"2556_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12931-019-0974-5","volume":"20","author":"B Bondue","year":"2019","unstructured":"Bondue B, Castiaux A, Van Simaeys G, Mathey C, Sherer F, Egrise D, et al. Absence of early metabolic response assessed by 18F-FDG PET\/CT after initiation of antifibrotic drugs in IPF patients. Respir Res. 2019;20:10. https:\/\/doi.org\/10.1186\/s12931-019-0974-5","journal-title":"Respir Res"},{"key":"2556_CR32","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1182\/blood-2005-08-3452","volume":"107","author":"KN Lee","year":"2006","unstructured":"Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun J-G, McKee PA. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood. 2006;107:1397\u2013404. https:\/\/doi.org\/10.1182\/blood-2005-08-3452","journal-title":"Blood"},{"key":"2556_CR33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1158\/2326-6066.CIR-13-0150","volume":"2","author":"JN Arnold","year":"2014","unstructured":"Arnold JN, Magiera L, Kraman M, Fearon DT. Tumoral Immune suppression by Macrophages expressing fibroblast activation protein-alpha and heme Oxygenase-1. Cancer Immunol Res. 2014;2:121\u20136. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0150","journal-title":"Cancer Immunol Res"},{"key":"2556_CR34","doi-asserted-by":"publisher","first-page":"30050","DOI":"10.18632\/oncotarget.16274","volume":"8","author":"Y Liao","year":"2017","unstructured":"Liao Y, Xing S, Xu B, Liu W, Zhang G. Evaluation of the circulating level of fibroblast activation protein \u03b1 for diagnosis of esophageal squamous cell carcinoma. Oncotarget. 2017;8:30050\u201362. https:\/\/doi.org\/10.18632\/oncotarget.16274","journal-title":"Oncotarget"},{"key":"2556_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijcard.2017.01.037","volume":"232","author":"J Tillmanns","year":"2017","unstructured":"Tillmanns J, Fraccarollo D, Galuppo P, Wollert KC, Bauersachs J. Changes in concentrations of circulating fibroblast activation protein alpha are associated with myocardial damage in patients with acute ST-elevation MI. Int J Cardiol. 2017;232:155\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2017.01.037","journal-title":"Int J Cardiol"},{"key":"2556_CR36","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.rmed.2011.11.006","volume":"106","author":"K Sakamoto","year":"2012","unstructured":"Sakamoto K, Taniguchi H, Kondoh Y, Wakai K, Kimura T, Kataoka K, et al. Acute exacerbation of IPF following diagnostic bronchoalveolar lavage procedures. Respir Med. 2012;106:436\u201342. https:\/\/doi.org\/10.1016\/j.rmed.2011.11.006","journal-title":"Respir Med"},{"key":"2556_CR37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1620\/tjem.174.379","volume":"174","author":"N Hiwatari","year":"1994","unstructured":"Hiwatari N, Shimura S, Takishima T, Shirato K. Bronchoalveolar Lavage as a possible cause of Acute Exacerbation in Idiopathic Pulmonary Fibrosis Patients. Tohoku J Exp Med. 1994;174:379\u201386. https:\/\/doi.org\/10.1620\/tjem.174.379","journal-title":"Tohoku J Exp Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02556-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02556-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02556-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T16:45:53Z","timestamp":1730393153000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02556-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2556"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02556-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3188251\/v1","asserted-by":"object"}]},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]},"assertion":[{"value":"20 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The collection of human samples was approved by the local Ethical Committee of Erasme Hospital (P2022\/587) and all patients signed an informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The society SOFIE\/iTheranostics kindly provided FAPI-74 but they were not involved in the study design, collection, analysis, interpretation of data and the writing of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"254"}}